Significance of CSF NfL and tau in ALS
- PMID: 30187162
- DOI: 10.1007/s00415-018-9043-0
Significance of CSF NfL and tau in ALS
Abstract
Cerebrospinal fluid (CSF) neurofilament light chain (NfL) has emerged as putative diagnostic biomarker in amyotrophic lateral sclerosis (ALS), but it remains a matter of debate, whether CSF total tau (ttau), tau phosphorylated at threonine 181 (ptau) and the ptau/ttau ratio could serve as diagnostic biomarker in ALS as well. Moreover, the relationship between CSF NfL and tau measures to further axonal and (neuro)degeneration markers still needs to be elucidated. Our analysis included 89 ALS patients [median (range) age 63 (33-83) years, 61% male, disease duration 10 (0.2-190) months] and 33 age- and sex-matched disease controls [60 (32-76), 49%]. NfL was higher and the ptau/ttau ratio was lower in ALS compared to controls [8343 (1795-35,945) pg/ml vs. 1193 (612-2616), H(1) = 70.8, p < 0.001; mean (SD) 0.17 (0.04) vs. 0.2 (0.03), F(1) = 14.3, p < 0.001], as well as in upper motor neuron dominant (UMND, n = 10) compared to classic (n = 46) or lower motor neuron dominant ALS [n = 31; for NfL: 16,076 (7447-35,945) vs. 8205 (2651-35,138) vs. 8057 (1795-34,951)], Z ≥ 2.5, p ≤ 0.01; for the ptau/ttau ratio: [0.13 (0.04) vs. 0.17 (0.04) vs. 0.18 (0.03), p ≤ 0.02]. In ALS, NfL and the ptau/ttau ratio were related to corticospinal tract (CST) fractional anisotropy (FA) and radial diffusivity (ROI-based approach and whole-brain voxelwise analysis). Factor analysis of mixed data revealed a co-variance pattern between NfL (factor load - 0.6), the ptau/ttau ratio (0.7), CST FA (0.8) and UMND ALS phenotype (- 2.8). NfL did not relate to any further neuroaxonal injury marker (brain volumes, precentral gyrus thickness, peripheral motor amplitudes, sonographic cross-sectional nerve area), but a lower ptau/ttau ratio was associated with whole-brain gray matter atrophy and widespread white matter integrity loss. Higher NfL baseline levels were associated with greater UMN disease burden, more rapid disease progression, a twofold to threefold greater hazard of death and shorter survival times. The findings that higher CSF NfL levels and a reduced ptau/ttau ratio are more associated with clinical UMN involvement and with reduced CST FA offer strong converging evidence that both are markers of central motor degeneration. Furthermore, NfL is a marker of poor prognosis, while a low ptau/ttau ratio indicates extramotor pathology in ALS.
Keywords: Amyotrophic lateral sclerosis; Cerebrospinal fluid; Diffusion tensor imaging; MRI; Neurofilament light chain; Ptau/ttau ratio; Tau phosphorylated at threonine 181 (ptau); Ttau.
Similar articles
-
Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis.JAMA Neurol. 2014 Apr;71(4):442-8. doi: 10.1001/jamaneurol.2013.6064. JAMA Neurol. 2014. PMID: 24492862 Free PMC article.
-
Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.J Neurol. 2020 Jun;267(6):1699-1708. doi: 10.1007/s00415-020-09761-z. Epub 2020 Feb 25. J Neurol. 2020. PMID: 32100123
-
Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis.Eur J Neurol. 2021 Jun;28(6):1868-1875. doi: 10.1111/ene.14789. Epub 2021 Mar 19. Eur J Neurol. 2021. PMID: 33638255
-
CSF and blood levels of Neurofilaments, T-Tau, P-Tau, and Abeta-42 in amyotrophic lateral sclerosis: a systematic review and meta-analysis.J Transl Med. 2024 Oct 21;22(1):953. doi: 10.1186/s12967-024-05767-7. J Transl Med. 2024. PMID: 39434139 Free PMC article.
-
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.Front Neurosci. 2021 Jun 21;15:679199. doi: 10.3389/fnins.2021.679199. eCollection 2021. Front Neurosci. 2021. PMID: 34234641 Free PMC article. Review.
Cited by
-
Increased CXCL12, a potential CSF biomarker for differential diagnosis of amyotrophic lateral sclerosis.Brain Commun. 2024 Aug 13;6(4):fcae271. doi: 10.1093/braincomms/fcae271. eCollection 2024. Brain Commun. 2024. PMID: 39188590 Free PMC article.
-
Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics.PLoS One. 2021 Nov 29;16(11):e0260323. doi: 10.1371/journal.pone.0260323. eCollection 2021. PLoS One. 2021. PMID: 34843548 Free PMC article.
-
Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS.Ann Clin Transl Neurol. 2019 Dec;6(12):2489-2502. doi: 10.1002/acn3.50943. Epub 2019 Nov 19. Ann Clin Transl Neurol. 2019. PMID: 31742901 Free PMC article.
-
Brevican and Neurocan Cleavage Products in the Cerebrospinal Fluid - Differential Occurrence in ALS, Epilepsy and Small Vessel Disease.Front Cell Neurosci. 2022 Apr 11;16:838432. doi: 10.3389/fncel.2022.838432. eCollection 2022. Front Cell Neurosci. 2022. PMID: 35480959 Free PMC article.
-
Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model.Front Neurosci. 2021 Apr 6;15:651651. doi: 10.3389/fnins.2021.651651. eCollection 2021. Front Neurosci. 2021. PMID: 33889072 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous